Alerts will be sent to your verified email
Verify Email
None
|
Wintac
|
|
|---|---|
|
Operational Metrics
|
|
|
Pharmaceuticals
|
|
|
R&D as a % of Total Sales
|
13.12 % |
|
Financials
|
|
|
5 yr Average ROE
|
78.06 % |
|
5yr average Equity Multiplier
|
-4.32 |
|
5yr Average Asset Turnover Ratio
|
0.65 |
|
5yr Avg Net Profit Margin
|
-8.7 % |
|
Price to Book
|
0.0 |
|
P/E
|
193.85 |
|
5yr Avg Cash Conversion Cycle
|
-191.8 Days |
|
Inventory Days
|
77.6 Days |
|
Days Receivable
|
24.76 Days |
|
Days Payable
|
266.89 Days |
|
5yr Average Interest Coverage Ratio
|
-2.44 |
|
5yr Avg ROCE
|
22.62 % |
|
5yr Avg Operating Profit Margin
|
0.23 % |
|
5 yr average Debt to Equity
|
-2.95 |
|
5yr CAGR Net Profit
|
n/a |
|
5yr Average Return on Assets
|
-5.26 % |
|
Shareholdings
|
|
|
Promoter Holding
|
54.99 % |
|
Share Pledged by Promoters
|
0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 |
|
Wintac
|
|
|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|